Ascentage Pharma to showcase 17 clinical advances at 2026 European Hematology Association Congress

Ascentage Pharma announced it will present 17 clinical advances, including 8 poster presentations, at the 31st European Hematology Association Congress in June 2026. Highlights include data on Olverembatinib, China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor. These presentations reflect ongoing clinical studies for cancer therapies, signaling progress in treatment options. The event gathers global hematology experts to share research and clinical breakthroughs.